Pfizer's 5.9% yield versus AbbVie's 53-year dividend streak
Alpha Vantage · The Globe and Mail · · AI-summarised by FinFlash
Pfizer offers a 5.9% dividend yield, while AbbVie pairs income with a 53-year streak of dividend increases and growth after navigating its own patent cliff. The comparison frames the choice as maximizing current cash flow versus combining income with consistent dividend growth. For income investors, Pfizer suits yield-first portfolios, while AbbVie appeals to those wanting rising payouts alongside growth.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.